The NeurologyLive® multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related and demyelinating disorders such as neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.
November 27th 2024
A recent multicenter study showed that dried blood spot testing for neuromyelitis optica spectrum disorder provided high accuracy and practicality in resource-limited settings.
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Little Voices, Big Challenges: Comprehensive Care for Pediatric Spinal Muscular Atrophy
January 9, 2025
Register Now!
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Carolina Neuromuscular Summit
September 27, 2025
Register Now!
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials
View More
Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors
View More
Genetic Targets Invigorate Research for Duchenne Muscular Dystrophy
February 22nd 2019Over the past several years, scientific teams have developed investigational methods for delivering a gene to correct a mutation in the DMD gene which causes DMD by creating dysfunction in a patient’s dystrophin production.
FDA Issues Warning About Misuse of Young Donor Plasma Infusions
February 19th 2019A joint statement from the FDA commissioner and the director of the agency’s Center for Biologics Evaluation and Research noted the product is being offered at a variety of establishments as a treatment for conditions for which its benefits are unproven.
FDA Issues Final Policy Framework for RMAT Designated Therapies
February 18th 2019The framework consists of 2 documents that expand on the agency’s plans for its risk-based approach for describing drugs, devices, and biologics, including those designated as regenerative medicine advanced therapies.
Could Vitamin D Be Leveraged as a Way to Treat Adrenoleukodystrophy?
February 15th 2019The assistant professor of neurology at Stanford University addressed the possibility that vitamin D’s role on cells within the human immune system could have a therapeutic influence in neuro-metabolic disorders such as ADL.
Temelimab Shows Promise in Multiple Sclerosis In Phase 1 Trial
February 5th 2019The phase 1 trial assessed high doses of the therapy in 24 healthy volunteers, divvied up into 4 cohorts to receive doses, including 36 mg/kg, 60 mg/kg, 85 mg/kg, and 110 mg/kg. These data build upon the findings of the phase 2b CHANGE-MS trial.
Alemtuzumab and Rituximab Found Safe and Effective in MS Post-Fingolimod Withdrawal
January 30th 2019Data has suggested that patients with multiple sclerosis who have withdrawn from treatment with fingolimod (Gilenya, Novartis) can safely be treated effectively with alemtuzumab (Lemtrada, Sanofi Genzyme) or rituximab (Rituxan, Genentech/Biogen).
Using Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
January 28th 2019The chief of the Division of Immunotherapy at the Northwestern University Feinberg School of Medicine discussed the results of the randomized clinical trial and the implications of this treatment in clinical practice.